Back to top
more

Myriad Genetics (MYGN)

(Delayed Data from NSDQ)

$25.36 USD

25.36
1,041,076

+0.43 (1.72%)

Updated May 14, 2024 04:00 PM ET

After-Market: $25.35 -0.01 (-0.04%) 5:08 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (92 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Sangamo Therapeutics (SGMO) in Focus: Stock Moves 13.6% Higher

Sangamo Therapeutics (SGMO) shares rose nearly 14% in the last trading session, amid huge volumes.

    Lexicon (LXRX) Looks Good: Stock Adds 7.6% in Session

    Lexicon (LXRX) was a big mover last session, as the company saw its shares rise more than 7% on the day amid huge volumes.

      Here's Why Investors Should Buy Myriad Genetics Right Now

      Myriad Genetics' (MYGN) recent collaborations are encouraging. Also, the company banks on the GeneSight and EndoPredict portfolios.

        Illumina Introduces NextSeq 550Dx, Updates Use of MiSeqDx

        Illumina (ILMN) expands NGS platform. The company has a solid diagnostic NGS portfolio, which includes NextSeq 550Dx and MiSeqDx.

          Myriad Genetics' Latest Alliance to Boost GeneSight Reach

          Myriad Genetics' (MYGN) tie-up with Department of VA to assess the effectiveness of GeneSight test buoys optimism. Also, favorable results might boost GeneSight's customer base

            Immunomedics (IMMU) Jumps: Stock Rises 5.4%

            Immunomedics (IMMU) was a big mover last session, as the company saw its shares more than 5% on the day amid huge volumes.

              Here's Why Investors Should Buy Luminex (LMNX) Right Now

              Luminex (LMNX) continues to grow strong on innovation and product launches.

                Haemonetics (HAE) Grows on Strong Plasma, Competition Rife

                Despite stiff competition, Haemonetics (HAE) grows on the back of its Plasma and Haemonetics Management franchises.

                  Quest Diagnostics, Clinical Genomics Ally, Oncology Strong

                  Quest Diagnostics' (DGX) plan to distribute Clinical Genomics' FDA-approved InSure ONE is in line with the company's objective to lead in the high-potential oncology diagnostic market.

                    Ophthotech (OPHT) Jumps: Stock Rises 11.9%

                    Ophthotech Corporation (OPHT) saw its shares rise nearly 12% on the day.

                      Medtronic Preliminary Sales Dip Y/Y, Hurricane Blow Lessens

                      Divestiture of certain businesses to Cardinal Health induces year-over-year decline in Medtronic's (MDT) preliminary sales figure. However, impact of Maria is likely to be lighter on the company's finances.

                        BioTelemetry (BEAT) Q3 Earnings Miss, Revenues Meet Estimates

                        A decline in gross and operating margin was a major drag for BioTelemetry (BEAT) in the third quarter.

                          Myriad Genetics (MYGN) Beats on Q1 Earnings & Revenues

                          Myriad Genetics (MYGN) rides high on strength in Molecular diagnostics with significant contributions from GeneSight. Also, Hereditary cancer tests continue to witness year-over-year volume growth.

                            What's in the Cards for DaVita (DVA) Stock in Q3 Earnings?

                            DaVita's (DVA) ongoing cost inflation might weigh on its margins in Q3. However, the Kidney Care business raises hope with steady investments in capital-efficient technologies.

                              Spectrum (SPPI) Earnings, Sales Beat Q3 Estimates

                              Spectrum (SPPI) reports narrower-than-expected loss in Q3. Shares up.

                                Zoetis (ZTS) Beats on Q3 Earnings & Sales, Ups 2017 View

                                Zoetis (ZTS) reported impressive third-quarter results beating estimates on both counts. Revenues were driven by strong demand for companion animal products worldwide.

                                  Is a Beat in Store for Ionis (IONS) This Earnings Season?

                                  Ionis Pharmaceuticals (IONS) earned $50 million in milestone payments from Biogen. Spinraza had a strong third quarter as announced by Biogen in its earnings results.

                                    Spectrum Pharmaceuticals (SPPI) Q3 Earnings: What's in Store?

                                    Spectrum Pharmaceuticals' (SPPI) Folotyn and Evomela drugs are expected to drive third-quarter sales. The company is progressing well with its pipeline candidates.

                                      Is ACADIA (ACAD) Likely to Beat Earnings Estimates in Q3?

                                      ACADIA Pharmaceuticals' (ACAD) antipsychotic drug, Nuplazid, is expected to record strong sales in the third quarter despite increased prices backed by higher demand.

                                        Can Molecular Diagnostics Drive Myriad's (MYGN) Q1 Earnings?

                                        Myriad Genetics (MYGN) is positioned to deliver solid results in Q1 on the back of the diversified Molecular Diagnostics portfolio with products like GeneSight and EndoPredict tests.

                                          Zacks.com featured highlights: Tyson Foods, Movado Group, Myriad Genetics, PRA Health Sciences and Urstadt Biddle Properties

                                          Zacks.com featured highlights: Tyson Foods, Movado Group, Myriad Genetics, PRA Health Sciences and Urstadt Biddle Properties

                                            Buy 5 Low-Beta Stocks & Forget Market Volatility

                                            We present a strategy that shows handsome return can be generated from investment in less risky stocks.

                                              Myriad Genetics Presents Favorable riskScore Test Data

                                              Myriad (MYGN) presenting positive riskScore data at the NSGC conference in Columbus, OH buoys optimism. Notably, with riskScore the company intends to boost its myRisk Hereditary Cancer test suite.

                                                Myriad Genetics Boosts myRisk Hereditary Cancer Test Suite

                                                Myriad Genetics (MYGN) introduces riskScore, a breast cancer prediction tool to broaden its myRisk hereditary cancer test offerings.

                                                  Myriad Genetics' EndoPredict Gets Positive Coverage Decision

                                                  Considering Myriad Genetics' (MYGN) EndoPredict has been used clinically in more than 15,000 patients, we are confident about the growing adaptability of this test post the Medicare coverage approval.